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Ceramides bind VDAC2 to trigger mitochondrial
apoptosis
Shashank Dadsena1,11, Svenja Bockelmann1,11, John G.M. Mina 1,2,11, Dina G. Hassan1,3,11, Sergei Korneev1,
Guilherme Razzera4,5, Helene Jahn1, Patrick Niekamp1, Dagmar Müller1, Markus Schneider1,6,7,
Fikadu G. Tafesse8, Siewert J. Marrink9, Manuel N. Melo 4,9 & Joost C.M. Holthuis1,7,10
Ceramides draw wide attention as tumor suppressor lipids that act directly on mitochondria
to trigger apoptotic cell death. However, molecular details of the underlying mechanism are
largely unknown. Using a photoactivatable ceramide probe, we here identify the voltage-
dependent anion channels VDAC1 and VDAC2 as mitochondrial ceramide binding proteins.
Coarse-grain molecular dynamics simulations reveal that both channels harbor a ceramide
binding site on one side of the barrel wall. This site includes a membrane-buried glutamate
that mediates direct contact with the ceramide head group. Substitution or chemical mod-
iﬁcation of this residue abolishes photolabeling of both channels with the ceramide probe.
Unlike VDAC1 removal, loss of VDAC2 or replacing its membrane-facing glutamate with
glutamine renders human colon cancer cells largely resistant to ceramide-induced apoptosis.
Collectively, our data support a role of VDAC2 as direct effector of ceramide-mediated cell
death, providing a molecular framework for how ceramides exert their anti-neoplastic activity.
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Sphingolipids are essential components of eukaryotic mem-branes that participate in a broad range of cellular processesby controlling vital physical membrane properties and as
signaling molecules in response to physiological cues and stres-
ses1–3. Notably ceramides, the central intermediates of sphingo-
lipid metabolism, have emerged as key mediators of anti-
proliferative and tumor suppressive cellular programs such as
apoptosis, mitophagy, cell cycle arrest, and senescence4,5. Multi-
ple stress stimuli, including tumor necrosis factor α (TNFα)6,7,
ionizing radiation8,9, and chemotherapeutic drugs10,11, cause a
rise in ceramide levels through stimulation of de novo ceramide
synthesis, activation of sphingomyelin hydrolysis, or both.
Interventions that suppress ceramide accumulation render cancer
cells resistant to these stress-inducing agents, indicating that
ceramides are bona ﬁde anti-proliferative and pro-apoptotic sig-
naling molecules. While these ﬁndings raised considerable
interest in targeting sphingolipid-metabolizing enzymes for can-
cer therapy5,12,13, the mechanisms by which ceramides execute
their tumor-suppressive activities are incompletely understood.
Mitochondria serve a central role in apoptosis induced by stress
stimuli. The mitochondria from cancer cells are often resistant to
induction of mitochondrial outer membrane permeabilization
(MOMP), a point of no return in the intrinsic pathway of apop-
tosis. MOMP allows the passage of intermembrane space proteins
such as cytochrome c to activate caspases, a family of cysteine
proteases responsible for executing an ordered destruction of the
cell14. MOMP is controlled by pro- and anti-apoptotic members
of the B-cell lymphoma 2 (Bcl-2) protein family, which collectively
determine the balance between cell death and survival15,16. The
main function of the anti-apoptotic Bcl2 proteins is to counter the
pro-apoptotic activities of the Bcl-2 proteins Bax and Bak, which
directly mediate MOMP by creating proteolipid pores responsible
for cytochrome c release17,18. Several reports have indicated that
ceramides can trigger MOMP by modulating the activity of
kinases or phosphatases implicated in controlling Bcl-2 protein
function. In cells, elevated ceramide levels have been shown to
inhibit phosphoinositide-3-kinase (PI3K) and Akt/PBK signaling,
resulting in dephosphorylation and subsequent activation of pro-
apoptotic Bcl-2-family protein Bad19,20. Short-chain ceramides
can bind and stimulate protein phosphatase 2A (PP2A), which
dephosphorylates and inactivates the anti-apoptotic protein
BCL221,22.
Other studies revealed that ceramides can also act directly on
mitochondria to trigger MOMP and apoptotic cell death23. For
instance, mitochondrial targeting of a bacterial sphingomyelinase
to generate ceramides in mitochondria or directing CERT-
mediated ceramide transport to mitochondria induces cyto-
chrome c release and apoptosis24,25. In addition, ER-like mem-
branes associated with isolated mitochondria appear to produce
sufﬁcient amounts of ceramides to enable a transient passage of
cytochrome c across the outer membrane26. However, the
underlying mechanisms remain to be established. Interestingly,
ceramides have been shown to form pores in model bilayers as
well as in the outer membrane of isolated mitochondria that are
large enough to mediate passage of cytochrome c27,28. Formation
of ceramide channels does not rely on any particular protein but
is disrupted by anti-apoptotic Bcl-2 proteins29. It has also been
suggested that ceramides accumulating in the mitochondrial
membrane of mammalian cells upon irradiation form or stabilize
microdomains that serve as platforms into which Bax inserts and
assembles into an active pore30. While ceramides have been
proposed to cooperate directly with Bax in the assembly of
cytochrome c conducting channels30,31, other experiments with
isolated mitochondria suggest that metabolic conversion of cer-
amides into sphingosine-1-phosphate and hexadecenal is neces-
sary to facilitate Bax/Bak activation leading to MOMP32.
In this study, we present evidence for an alternative mechan-
istic view, namely that ceramides mediate their pro-apoptotic
activity at least in part by interacting directly and speciﬁcally with
the voltage-dependent anion channel VDAC2, a mitochondrial
platform for Bax/Bak translocation33–35. Identiﬁcation of VDAC2
as an effector of ceramide-mediated cell death provides new
opportunities for exploiting the therapeutic potential of ceramides
as tumor suppressor lipids.
Results
A chemical screen for ceramide-binding proteins yields
VDACs. To identify proteins involved in ceramide-mediated
stress signaling and apoptosis, we used a bifunctional ceramide
analog carrying a photoactive diazirine and clickable alkyne
group in its N-linked acyl chain (pacCer, Fig. 1a)36. Total
membranes from human HeLa cells were incubated with pacCer-
containing liposomes, subjected to UV crosslinking and click
reacted with Alexa Fluor 647 azide (AF647-N3). In-gel ﬂuores-
cence (IGF) analysis revealed a subset of membrane-bound pro-
teins with afﬁnity for the pacCer probe, which included a
mitochondria-associated protein of ~33 kDa that was promi-
nently photolabeled (Fig. 1b, Supplementary Fig. 1). As ceramide
exerts its apoptogenic activity in mitochondria8,24,25, we set out to
identify the 33 kDa candidate ceramide-binding protein (CBP).
To this end, mitochondria were photolabeled with pacCer and
then click reacted with a PEG-based reagent containing an azide,
a biotin and a TAMRA ﬂuorophore as functional groups (Fig. 1c).
Next, pacCer-crosslinked proteins were isolated using Neu-
trAvidin agarose and visualized by IGF (Fig. 1d). The ﬂuorescent
33 kDa protein band was cut from the gel, trypsin-digested, and
identiﬁed by LC-MS/MS analysis as the voltage-dependent anion
channel isoforms VDAC1 and VDAC2 (Supplementary Table 1).
In line with the MS data, pretreatment of HeLa cells with VDAC1
and VDAC2-targeting siRNAs effectively depleted the ﬂuorescent
33 kDa protein band from pacCer-labeled and Alexa click-reacted
mitochondria (Fig. 1e, f). The photolabeled 33 kDa protein band
also cross-reacted with both anti-VDAC1 and anti-VDAC2
antibodies (Fig. 1g, h). In contrast, VDAC3 and TOM40—an
outer mitochondrial membrane (OMM) channel protein with a
cellular copy number close to that of VDACs37—both lacked
afﬁnity for pacCer, indicating that VDAC1 and VDAC2 are
genuine mitochondrial CBPs.
MD simulations uncover a ceramide-binding site on VDACs.
To search for a putative ceramide-binding site on VDAC1 and
VDAC2, we performed coarse-grain molecular dynamics (CG-
MD) simulations using the Martini model38–40. Main simulations
were performed with VDAC channels at an aggregate time of
1.23 ms (Supplementary Table 2)—only attainable using CG-MD.
A well-resolved structure of mouse VDAC1 (PDB: 4C69)41 was
used as a base template. An available structure of VDAC2 from
zebraﬁsh (PDB:4BUM)42 showed almost perfect structural iden-
tity to VDAC1 (1.7 Å barrel backbone RMSD). From the
assumption of identical secondary structure we mutated
VDAC1 side chains to the mouse sequences of VDAC2 and
VDAC3 to obtain all three isoforms for comparison. A bilayer
mimicking the OMM43 was constructed with ~630 lipids. To the
outer leaﬂet of this bilayer, 16 molecules of C16-ceramide were
added. In agreement with the photolabeling data, simulations
revealed that VDAC1 and VDAC2, but not VDAC3, have a
binding site for ceramide buried in the membrane interior on one
side of the barrel wall, comprising β-strands 3–5 (Fig. 2a). This
site harbors a uniquely positioned glutamate (Glu) residue in the
transmembrane region of β-strand 4—Glu73 in VDAC1 and
Glu84 in VDAC2—that faces the bilayer’s hydrophobic core
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(Fig. 2b). In its deprotonated state, this residue seemed to pro-
mote direct contact with the ceramide head group (Fig. 2c;
Supplementary Information Videos 1 and 2). In VDAC3, which
does not bind ceramide (Figs. 1h and 2a), the bilayer-facing Glu
residue is replaced by a glutamine (Gln73; Fig. 2b). Substitution of
Gln for Glu73 in VDAC1 or Glu84 in VDAC2 strongly reduced
the ceramide occupancy and residence time at the binding sites
(Fig. 2d, e). Protonation of the bilayer-facing Glu also greatly
diminished ceramide-binding (Fig. 3a, b) while substitution of a
deprotonated aspartate for the Glu residue retained ceramide
binding (Supplementary Fig. 2). This indicates that a negative
charge on the membrane-buried Glu residue is critical for cer-
amide binding.
In line with a previous computational study44, we also found a
number of binding sites for cholesterol. These displayed no
overlap with the ceramide-binding site (Fig. 2d). To exclude the
possibility that competition with ceramide prevented cholesterol
to occupy the ceramide-binding site, additional simulations were
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Fig. 1 A chemical screen for mitochondrial ceramide-binding proteins yields VDAC1 and -2. a Structure of the photoactive and clickable C15-ceramide
analog, pacCer. b Mitochondria isolated from HeLa cells were incubated with liposomes containing increasing amounts of pacCer, UV irradiated, and then
click reacted with AF647-N3. Samples were processed for SDS-PAGE, subjected to in-gel ﬂuorescence (IGF, red), and stained with Coomassie blue (CB,
blue). p33•Cer denotes a prominently photolabeled protein band of ~33 kDa. c Strategy for the identiﬁcation of p33•Cer. d p33•Cer was puriﬁed from
pacCer-labeled and TAMRA/biotin click-reacted mitochondria using NeutrAvidin-beads, imaged by IGF, excised from the gel, digested by trypsin, and then
identiﬁed by LC-MS/MS. Data from two independent experiments revealed that p33•Cer corresponds to VDAC1 and VDAC2. e Speciﬁcity of anti-VDAC
antibodies was validated by immunoblotting of mitochondria isolated from HeLa cells treated with non-silencing (siNS) or VDAC-targeting siRNAs
(siVDAC1, siVDAC2). Note that the anti-VDAC3 antibody cross-reacts with VDAC2. f Mitochondria isolated from siVDAC1/2-treated HeLa cells were
photolabeled with pacCer, click-reacted with AF647-N3, and subjected to IGF analysis followed by CB staining. g Fractions obtained during afﬁnity
puriﬁcation of p33•Cer were subjected to SDS-PAGE, transferred on nitrocellulose, analyzed by on-blot-ﬂuorescence (OBF) and probed with antibodies
against VDAC1, TOM40, and p60-Mito. h Fractions obtained during afﬁnity puriﬁcation of p33•Cer were processed as in g and probed with anti-VDAC2
and anti-VDAC3 antibodies. T total mitochondria extract, FT ﬂow-through, W wash, E eluate
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09654-4 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:1832 | https://doi.org/10.1038/s41467-019-09654-4 | www.nature.com/naturecommunications 3
performed in the absence ceramide. Also in those simulations no
cholesterol binding near the membrane-facing Glu was observed
(Supplementary Fig. 3). We observed zero-speciﬁc binding events
between phosphatidylcholine (PC) and VDACs in the OMM
mimics. Yet when VDAC1 was simulated in a bilayer of 100%
dimyristoyl-phosphatidylcholine (DMPC) following the setup of
a previous atomic resolution simulation analysis45, contacts of the
PC head group with the bilayer-facing deprotonated Glu residue
could occasionally be observed (Supplementary Fig. 4a). How-
ever, these encounters were much shorter-lived (≤5 ns; Supple-
mentary Fig. 4b) and extremely rare in comparison to those
involving ceramide, which displayed average residence times of
0.8 and 1.2 μs for VDAC1 and VDAC2, respectively (Supple-
mentary Fig. 4c). In sum, CG-MD simulations revealed that
VDAC1 and VDAC2 each harbor a binding site for ceramide,
with a charged Glu residue buried in the membrane interior
serving a critical role in ceramide binding.
Ceramide binding relies on a membrane-facing glutamate. We
next sought to verify the relevance of the membrane-facing Glu
residue in VDACs for ceramide binding. To this end, human
VDAC1 and VDAC2 and the mutant channels VDAC1E73Q and
VDAC2E84Q were produced recombinantly in E. coli and then
reconstituted in egg PC liposomes (Supplementary Fig. 5). Den-
sity gradient fractionation analysis revealed that reconstitution
efﬁciencies of wild type and mutant channels were practically
indistinguishable. The reconstituted channels were then subjected
to photolabeling with pacCer and bifunctional analogs of dia-
cylglycerol (pacDAG), PC (pacPC), phosphatidylethanolamine
(pacPE), and cholesterol (pacChol; Supplementary Fig. 6).
VDAC1 and VDAC2 could be efﬁciently and reproducibly pho-
tolabeled with pacCer, pacPC, and pacChol, but not with pac-
DAG or pacPE (Fig. 4). In agreement with the simulations,
replacing the membrane-facing Glu with Gln virtually abolished
labeling of both channels with pacCer and pacPC, whereas
labeling with pacChol was not or only slightly affected (Figs. 4
and 5a). Moreover, reducing the pH from 7 to 5 caused a sig-
niﬁcant reduction in E73-dependent photolabeling of VDAC1
with pacCer (Fig. 3c, d). This suggests that ceramide binding is
critically dependent on the protonation state of the membrane-
exposed Glu, as predicted by the simulations.
The pronounced labeling of the wild-type channels with pacPC
was somewhat unexpected as simulations revealed that speciﬁc
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Fig. 2 MD simulations uncover a putative ceramide-binding site on VDAC1 and -2. a Ceramide head group contact occupancy of mouse VDAC1, VDAC2,
and VDAC3 in an OMMmodel containing 5mol% ceramide, with 1.0 corresponding to a ceramide contact during the entire simulation time. A threshold of
15% occupancy, based on the occupancies of non-binding site residues, is indicated by a dotted blue line. VDAC1 and VDAC2 have a clear ceramide-
binding site, comprising residues 58–62, 71–75, and 81–85; this site is lacking in VDAC3. b Sequence alignment revealing the position of a bilayer-facing Glu
residue in VDAC1 (E73) and VDAC2 (E84), which is replaced by Gln in VDAC3 (Q73). c Stills from an MD simulation, showing the approach and binding
of a ceramide molecule to VDAC1 in close proximity of the bilayer-facing Glu residue in its deprotonated state. Protein surface colors mark polar (green),
apolar (white), cationic (blue), or anionic (red) residues. d Space-ﬁlling and wireframe models of VDAC1, VDAC1E73Q, VDAC2, and VDAC2E84Q with
deprotonated E73/E84. Indicated are the volumes for which there is ceramide occupancy greater than 10% (orange) or cholesterol occupancy greater than
20% (yellow). e Distribution of the durations of ceramide contacts with VDAC1, VDAC1E73Q, VDAC2, and VDAC2E84Q at the preferred binding site as in d.
The y-axis indicates the fraction of the total system time spent in binding events of the duration indicated by x. Summing all points’ y-values yields the
fraction of total simulation time when ceramide was bound
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encounters of PC molecules with the membrane-facing Glu are
relatively rare. This discrepancy could be due to the irreversible
nature of photoafﬁnity labeling in combination with the major
difference in timescales between CG-MD simulations (μs range)
and photoafﬁnity labeling (second range). While our data
revealed no obvious overlap between the ceramide and cholesterol
binding sites on VDACs, a recent photolabeling study mapped
the bilayer-facing Glu to a major cholesterol binding pocket on
VDAC146. In contrast to the present work, the latter study was
performed on VDAC1-containing bicelles with cholesterol probes
that carry the photoactive diazirine in the aliphatic tail or at C7.
Thus, additional work will be necessary to resolve the discrepancy
between the simulations and photolabeling studies of cholesterol
binding to VDACs.
As aliphatic diazirines display photochemical preference for
nucleophilic amino acids47, the deprotonated side chain of the
membrane-buried Glu in VDACs may provide a site of insertion
for the diazirine in pacCer, which may diffuse a short distance to
reach such a nucleophile. Therefore, we next labeled VDACs with
pacCer in the presence of excess C16-ceramide. Labeling by
pacCer was progressively reduced by C16-ceramide when added
in 3- to 27-fold excess (Fig. 5b), arguing against the idea that
pacCer labeling of VDACs is primarily driven by afﬁnity of the
aliphatic diazirine for the negatively charged Glu. Excess C16-
ceramide did not affect labeling of VDACs with pacChol. In line
with the simulations, these data indicate that ceramides bind
VDACs at the membrane-facing Glu residue. To verify that this
concept not only holds for recombinant channel proteins in
synthetic bilayers but also for their native counterparts in
mitochondrial membranes, we made use of the carboxyl-
modifying reagent dicyclohexylcarbodiimide (DCCD). This
hydrophobic compound irreversibly reacts with a number of
integral membrane proteins through covalent modiﬁcation of
membrane-embedded Asp or Glu residues and was previously
shown to modify Glu73 in VDAC148. Pretreatment of
mitochondria with DCCD selectively abolished photolabeling of
the 33 kDa protein band with pacCer (Supplementary Fig. 7),
hence providing complementary proof that the membrane-facing
Glu residue in VDAC1 and VDAC2 is part of an authentic
ceramide-binding site.
Loss of VDAC2 disrupts ceramide-induced apoptosis. VDAC
channels are active participants in the cytosolic release of apop-
togenic proteins from mitochondria. VDAC2 serves as a platform
for the mitochondrial recruitment of pro-apoptotic Bcl-2 proteins
Bak and Bax33–35, which can commit cells to death by permea-
bilizing the OMM for cytochrome c17,18. In response to various
apoptotic stimuli, VDAC1 forms oligomers and participates in
the assembly of a cytochrome c-conducting pore49,50. Identiﬁca-
tion of a ceramide-binding site on VDAC1 and VDAC2 raised
the question whether ceramides exert their apoptotic activity by
interacting with these proteins. To address this, we employed an
engineered ceramide transfer protein equipped with an OMM
anchor, mitoCERT (Fig. 6a). We previously demonstrated that
human HCT116 colon cancer cells expressing mitoCERT
undergo Bax-dependent apoptosis by mistargeting newly syn-
thesized ER ceramides to mitochondria (Fig. 6b)25. This led us to
determine the impact of VDAC removal on mitoCERT-induced
apoptosis in HCT116 cells. Loss of VDAC1, VDAC2, or both was
veriﬁed by immunoblotting and IGF analysis of mitochondria
photolabeled with pacCer (Supplementary Fig. 8). Expression of
mitoCERT in wild-type HCT116 cells triggered apoptosis, as
indicated by cleavage of caspase substrate PARP1 (Fig. 6c). No
PARP1 cleavage was observed in cells expressing a mitoCERT
variant that lacked the ceramide transfer or START domain,
mitoCERTΔSTART. Loss of VDAC1 had no effect on the ability
of mitoCERT to induce PARP1 cleavage. In contrast, VDAC2
removal rendered cells partially resistant to mitoCERT-induced
PARP1 cleavage, especially in the absence of VDAC1 (Fig. 6c).
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Glu84 in VDAC2 is critical for ceramide-induced apoptosis.
We next analyzed individual wild type and ceramide-binding
defective VDAC channels for their ability to support mitoCERT-
induced apoptosis. To this end, HCT116 VDAC1/2 double KO
cells were stably transduced with haemagglutinin (HA)-tagged
VDAC1, VDAC1E73Q, VDAC2, or VDAC2E84Q (Fig. 7a). Mito-
chondrial localization of the tagged channels was conﬁrmed by
immunoﬂuorescence microscopy (Supplementary Fig. 9). Het-
erologous expression of VDAC2, but not VDAC1, restored
mitoCERT-induced apoptosis in the double KO cells, as evi-
denced by PARP1 cleavage and proteolytic activation of caspase-
3, the principal executioner caspase in apoptotic cells (Fig. 7a–c).
This conﬁrmed that VDAC2, unlike VDAC1, is a key player in
ceramide-mediated cell death. Strikingly, replacing Glu84 with
Gln in VDAC2 greatly reduced its ability to support mitoCERT-
induced apoptosis in the double KO cells (Fig. 7a–c), indicating
that cell death triggered by a rise in mitochondrial ceramides
requires a ceramide-binding competent form of VDAC2. While
VDAC1 or VDAC2 removal had no major impact on cellular Bax
levels, cells lacking VDAC2 had strongly reduced Bak levels
(Supplementary Fig. 10a), consistent with the unique role of
VDAC2 in stabilizing Bak33. Reintroducing VDAC2 or VDA-
C2E84Q in VDAC1/2 double KO cells in each case fully restored
Bak levels to those in wild-type cells (Supplementary Fig. 10b),
indicating that an intact ceramide-binding site is dispensable for
VDAC2-mediated stabilization of Bak. This notion is supported
by the ﬁnding that the Bak-stabilizing activity of VDAC2 requires
isoform-speciﬁc sequence motifs located outside of the region
involved in ceramide binding33.
Discussion
The current study identiﬁed a role of VDAC2 as a direct and
speciﬁc effector of ceramide-mediated cell death. This function
critically relies on a uniquely positioned charged Glu residue that
mediates direct contact with the ceramide head group in the
bilayer interior, potentially driven by electrostatic attraction. We
speculate that an amide-containing backbone combined with a
small polar head group renders ceramide the preferred lipid
binding partner of VDAC isoforms containing the membrane-
buried Glu residue. Although it is energetically unfavorable for
charged residues to face the bilayer’s hydrophobic core, recent
work revealed that the pKa of Glu73 in VDAC1 is closely tuned to
the physiological pH of the cytosol (pKa ~7.4)51. This implies that
under stress-free conditions, the membrane-buried Glu is in its
deprotonated fully charged state at least a signiﬁcant amount of
time. Interestingly, ceramide binding to the late endosomal pro-
tein LAPTM4B depends on a membrane-embedded aspartate52.
We anticipate that also other proteins with charged acidic resi-
dues in their membrane spans may have afﬁnity for ceramide and
potentially participate in ceramide-operated signaling pathways.
While ceramide-induced apoptosis requires Bax8,24,25, a recent
study revealed that VDAC2 speciﬁes Bax recruitment to
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mitochondria and concomitantly ensures Bax inhibition by
mediating its retrotranslocation into the cytosol34. By establishing
a dynamic equilibrium between mitochondrial and cytosolic Bax
pools, this VDAC2-dependent shuttling is ideally suited for reg-
ulation by pro- and anti-apoptotic cues. Our present ﬁndings
suggest that ceramide binding to VDAC2 may commit cells to
death by blocking Bax retrotranslocation. This concept is distinct
from previous models postulating that ceramides accumulating in
the OMM: (i) self-assemble into cytochrome c-conducting
channels27,28; (ii) form lipid macrodomains into which Bax
inserts and functionalizes as a pore30,31; (iii) affect mitochondrial
shape to facilitate Bax recruitment and apoptosis53; (iv) require
metabolic conversion to gain apoptogenic activity32.
How ceramide binding tips the balance in VDAC2-mediated
shuttling of Bax to trigger mitochondrial apoptosis remains to be
established. Our simulations and photoafﬁnity experiments
35
25
35
25
IGF
CB
kDa
35
25
35
25
IGF
CB
kDa
35
25
35
25
IGF
CB
35
25
25
35
kDa
35
25
25
35
35
25
25
35
kDa
35
25
25
35
5 2 0.5 0.2 0.05 0nmol:
IGF
CB
IGF
CB
5 2 0.5 0.2 0.05 0nmol:
pacCer
VDAC1
VDAC1
VDAC1
VDAC1
pacChol
a
5 2 0.8 0.3 0.1 0nmol:
IGF
CB
IGF
CB
5 2 0.8 0.3 0.1 0nmol:
pacCer
VDAC2
VDAC2
VDAC2
VDAC2
pacChol
No
 pa
cC
er
b
VDAC1
VDAC1
125
100
75
50
25
0
x:
VDAC2
VDAC2
125
100
75
50
25
0p
ac
Ce
r l
ab
el
in
g 
(%
 of
 m
ax
)
x:
VDAC2
VDAC2
125
100
75
50
25
0
VDAC1
VDAC1
x:
WT E/Q WTE/Q WT E/QWTE/Q WTE/Q WT E/Q
125
100
75
50
25
0
VDAC1 VDAC2
0.2 nmol pacCer + x nmol Cer
0 0.2 0.6 1.8 5.4 0x:
VDAC1 VDAC2
VDAC1 VDAC2
*
**
**
***
NS NS
35
25
35
25
IGF
CB
WT E/Q WTE/Q WT E/QWTE/Q WTE/Q WT E/Q
WT E/Q WTE/Q WT E/QWTE/Q WTE/Q WT E/Q WT E/Q WTE/Q WT E/QWTE/Q WTE/Q WT E/Q
WT E/Q WTE/Q WT E/QWTE/Q WTE/Q WT E/QWT E/Q WTE/Q WT E/QWTE/Q WTE/Q WT E/Q
WT E/Q WTE/Q WT E/QWTE/Q WTE/Q WT E/Q WT E/Q WTE/Q WT E/QWTE/Q WTE/Q WT E/Q
WT E/Q WTE/Q WT E/QWTE/Q WTE/Q WT E/Q WT E/Q WTE/Q WT E/QWTE/Q WTE/Q WT E/Q
WT E/Q WTE/Q WT E/QWTE/Q WTE/Q WT E/QWT E/Q WTE/Q WT E/QWTE/Q WTE/Q WT E/Q
0 0.2 0.6 1.8 5.4 0 0 0.2 1.8 5.4 7.2 0
0 0.2 1.8 5.4 7.2 0
0.2 nmol pacChol + x nmol Cer 0.2 nmol pacChol + x nmol Cer
0.2 nmol pacCer + x nmol Cer
pa
cC
ho
l la
be
lin
g 
(%
 of
 m
ax
) 
pa
cC
ho
l la
be
lin
g 
(%
 of
 m
ax
) 
pa
cC
er
 la
be
lin
g 
(%
 of
 m
ax
)
No
 pa
cC
ho
l
No
 pa
cC
ho
l
No
 pa
cC
er
Fig. 5 Competitive inhibition of pacCer photolabeling of VDACs by C16-ceramide. a VDAC1, VDAC1E73Q, VDAC2, and VDAC1E84Q proteoliposomes were
photolabeled with the indicated amount of pacCer or pacChol added from ethanolic stocks. Next, samples were click-reacted with AF647-N3, subjected to
SDS-PAGE, and analyzed by IGF and CB staining. b VDAC1, VDAC1E73Q, VDAC2, and VDAC1E84Q proteoliposomes were photolabeled with 0.2 nmol
pacCer or pacChol in the presence of the indicated amounts of natural C16-ceramide (Cer) added from ethanolic stocks and then processed as in a. Relative
labeling efﬁciencies were quantiﬁed and expressed as % of control (0.2 nmol pacCer or pacChol in the absence of Cer). Data are means ± s.d.; n= 3; *p <
0.05, **p < 0.01, and ***p < 0.001 by two-tailed paired t-test. Source data
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09654-4 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:1832 | https://doi.org/10.1038/s41467-019-09654-4 | www.nature.com/naturecommunications 7
indicate that ceramide binding to VDACs is pH sensitive and
controlled by the protonation state of the membrane-buried Glu.
Interestingly, acidiﬁcation has been shown to promote association
of two VDAC1 monomers into a dimer51. Assembly of a high-
afﬁnity dimer relies on protonation of the membrane-facing Glu
(E73) and likely involves hydrogen bonding between this residue
and a serine (Ser43) at the dimer interface51. VDAC oligomer-
ization has been implicated as a component of the mitochondrial
pathway of apoptosis49,50 and may be part of the mechanism by
which VDAC2 stabilizes the mitochondrial pool of Bax in
response to apoptotic stimulation34. In view of our present
ﬁndings, a prospect that merits further investigation is whether
binding of ceramide to the charged Glu residue lowers the
threshold for VDAC oligomerization at neutral pH. Ceramide
binding to VDACs may also inﬂuence interactions with other
proteins, as the membrane-facing Glu residue is critical for
association of VDAC1 with hexokinase I54,55. VDAC-bound
hexokinases are thought to play a pivotal role in promoting cell
growth and survival in rapidly growing, hyperglycolytic
tumors56,57. Consequently, our current study establishes a
molecular framework to unravel how ceramides execute their
tumor suppressor functions.
Methods
Reagents. 1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dioleoyl-sn-
glycero-3-phosphoethanol-amine (DOPE), and L-α-phosphatidylcholine from
chicken egg (egg PC), 1-palmitoyl-2-{12-[(7-nitro-2-1,3-benzoxadiazol-4-yl)
amino]dodecanoyl}-sn-glycero-3-phosphocholine (NBD-PC) and C16-ceramide
(d18:1/16:0) were purchased from Avanti Polar Lipids. Alexa Fluor 647-N3
(AF647-N3) and Biotin-N3 were from Thermo Fischer Scientiﬁc, and TAMRA-
Biotin-N3 from Click Chemistry Tools. The photoactive and clickable trans-sterol
probe (pacChol) was from Sigma-Aldrich. A 15 carbon-long fatty acid containing a
photoactivatable diazerine and clickable alkyne group, pacFA, was synthesized in
three steps from commercially available educts36. Next, pacFA was coupled to D-
erythro-sphingosine (Enzo Biochem) using a combination of 1-ethyl-3-(3-dime-
thylaminopropyl)carbodiimide (EDCI) and hydroxybenzotriazole (HOBT) as
condensing reagents, yielding the photoactivatable and clickable C15-ceramide
analog, pacCer (85% overall yield). pacPC was synthesized starting from 1-oleoyl-
2-hydroxy-sn-glycero-3-phosphocholine (Avanti Polar Lipids) and pacFA under
the action of N,N-dicyclohexylcarbodiimide (DCC) and 4-dimethylaminopyridine
(DMAP) with satisfactory yield (39%). pacDAG was synthesized in three steps
starting from 1-oleoyl-sn-glycerol (Santa Cruz Biotechnology). First, the primary
HO-group was protected with the triphenylmethyl protecting group (trityl-chlor-
ide/pyridine; 92% overall yield). The 1-acyl-3-trityloxy-glycerol obtained was
coupled with the pacFA using EDCI/DMAP activation (58% overall yield). The
ﬁnal deprotection step was achieved using triﬂuoroacetic acid (TFAA) to generate
pacDAG (28% overall yield). pacPE was synthesized in three steps starting from 1-
oleoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine (Avanti Polar Lipids). First,
the amino-group was protected with the tert-butoxycarbonyl protecting group (di-
tert-butyldicarbonate/triethylamine; 98% overall yield). The N-protected lyso-PE
obtained was coupled with pacFA using EDCI/DMAP activation in a good yield
(52%). The ﬁnal deprotection step was achieved with TFAA to generate pacPE
(35%, overall yield).
Antibodies. Antibodies used were mouse monoclonal anti-β-actin (Sigma-Aldrich,
A1978; IB 1:50,000), rabbit polyclonal anti-FLAG (Cell Signaling, 2368; IB 1:1,000),
mouse monoclonal anti-mitochondrial surface protein p60 (Millipore, MAB1273;
IB 1:1,000), rabbit polyclonal anti-VDAC1 (Cell Signaling, 4661; IB 1:1,000), goat
polyclonal anti-VDAC2 (Abcam, Ab37985; IB 1:1,000), rabbit polyclonal anti-
VDAC3 (Abcam, Ab80452; IB 1:1,000), mouse monoclonal anti-TOM20 (Milli-
pore, Mabt166; IF 1:200), rabbit polyclonal anti-TOM40 (Abcam, Ab185543; IB
1:1,000), rabbit polyclonal anti-HA (Invitrogen, 715500; IB 1:1,000; IF 1:200), rat
monoclonal anti-HA (Roche, 12158167001; IB 1:1,000), rabbit monoclonal anti-
Bax (Cell Signaling, 5023; IB 1:1,000), rabbit polyclonal anti-cleaved caspase-3 (Cell
Signaling, 96611; IB 1:1,000), mouse monoclonal anti-PARP-1 (Santa Cruz, sc8007;
IB 1:1,000) and rabbit polyclonal anti-calnexin (Santa Cruz, sc11397; IB 1:1,000).
Goat anti-mouse (31430; IB 1:5,000), goat anti-rabbit (31460; IB 1:5,000) and
donkey anti-goat IgG conjugated to horseradish peroxidase (pa1-28664; IB 1:5,000)
were from Thermo Fischer Scientiﬁc. Cy™-dye-conjugated donkey anti-mouse and
donkey anti-rabbit antibodies (715-225-150, 715-225-152, 715-165-150, 715-165-
152, 715-175-150 and 715-175-152; IF 1:250 each) were from Jackson Immu-
noResearch Laboratories.
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DNA constructs. For expression of human VDACs in E. coli, the corresponding
cDNAs were PCR ampliﬁed using Phusion high-ﬁdelity DNA polymerase (Thermo
Fischer Scientiﬁc) and inserted via NdeI and XbaI (VDAC1) or XhoI and XbaI sites
(VDAC2) into bacterial expression vector pCold I (Takara Bio, USA). For retro-
viral transduction studies, DNA fragments encoding human VDACs with a C-
terminal HA tag (YPYDVPDYA) were created by PCR and inserted via NotI and
XhoI sites into lentiviral expression vector pLNCX2 (Takara Bio, USA). Single
amino acid substitutions were introduced using the QuikChange II site-directed
mutagenesis method (Alignet, USA). Primers used for cloning and site-directed
mutagenesis are listed in Supplementary Table 3. Mammalian expression con-
structs encoding FLAG-tagged mitoCERT and mitoCERTΔSTART were described
previously25. All expression constructs were veriﬁed by DNA sequencing.
Cell culture and transfection and RNAi. Human cervical carcinoma HeLa cells
(ATCC CCL-2) were cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM)
supplemented with 4.5 g/l glucose, 2 mM L-glutamine and 10% FBS. Human colon
carcinoma HCT116 cells (ATCC CCL-247) were cultured in McCoy’s medium
supplemented with 10% FBS. Human embryonic kidney HEK293T cells (ATCC
CRL-3216) were cultured in DMEM supplemented with 10% FBS. Cells were
transfected with DNA constructs using Effectene (Qiagen) according to the
manufacturer’s instructions unless stated otherwise. Treatment of HeLa cells with
siRNA (Qiagen) was performed using Oligofectamine reagent (Invitrogen)
according to the manufacturer’s instructions. siRNA target sequences were: NS
(nonsense), 5′-AAUUCUCCGAACGUGUCACGU-3′; VDAC1, 5′-ACACUA
GGCACCGAGAUUAUU-′3; VDAC2, 5′-AAUACAAGUGGUGUGAGUAUU-3′.
Generation of VDAC KO cell lines. To knock out VDAC1 and VDAC2 in
HCT116 cells, we obtained a mix of three different CRISPR/Cas9 plasmids per gene
and the corresponding HDR plasmids from Santa Cruz (sc-418200, sc-416966).
The VDAC1-speciﬁc gRNA sequences were: A/sense, 5′-TTGAAGGAATTTACA
AGCTC-3′; B/sense, 5′-CGAATCCATGTCGCAGCCC-3′; C/sense, 5′-CTTACA
CATTAGTGTGAAGC-3′. The VDAC2-speciﬁc gRNA sequences were: A/sense,
5′-AGAAATCGCAATTGAAGACC-3′; B/sense, 5′-GCCCTTAAGCAGCACAG
CAT-3′; C/sense, 5′-TAATGTGACTCTCAAGTCCT-3′. HCT116 cells were
transfected with both plamid mixes and grown for 48 h without selection. Next,
cells were grown for 2 weeks under selective pressure with 2 µg/ml puromycin.
Individual drug-resistant clones were picked and analyzed for VDAC1 and VDAC2
expression by immunoblot analysis. A VDAC1/2 double KO cell line was generated
from ΔVDAC1 cells as described above following ejection of the puromycin
selectable marker using Cre vector (Santa Cruz, sc-418923) according to the
manufacturer’s instructions.
Retroviral transduction. HCT116 VDAC1/2 double KO cells stably expressing
HA-tagged VDAC1, VDAC1E73Q, VDAC2, or VDAC2E84Q were created by ret-
roviral transduction. To this end, HEK293T cells were co-transfected with pLNX2-
VDAC-HA expression constructs and packaging vectors (Clontech) using Lipo-
fectamine 3000 (Invitrogen) according to the manufacturer’s instructions. The
culture medium was changed 6 h post transfection. After 48 h, the retrovirus-
containing medium was harvested, ﬁltered through a 0.45 µm ﬁlter, mixed
1:1 (v/v) with McCoy’s growth medium, supplemented with 8 µg/ml polybrene,
and used to transduce HCT116 VDAC1/2 double KO cells. Hygromycin (300 µg/
ml) was added 6 h post-infection and selective medium was exchanged daily. After
3–5 days, positively transduced cells were selected and analyzed for
expression of HA-tagged VDACs by immunoblot analysis and immuno-
ﬂuorescence microscopy.
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Reconstitution of recombinant VDACs. VDAC-encoding pCold I constructs
were transformed in E. coli BL21 (DE3) ΔOmp9 cells (a kind gift from Dr. Lars-
Oliver Essen, Philips-Universität Marburg, Germany). Transformants were grown
at 37 °C to early exponential phase in LB medium containing 100 μg/ml ampicillin
and cooled for 30 min at 4 °C prior to addition of 1 mM IPTG. Growth was
continued for 24 h at 15 °C. Cells were collected by centrifugation and lysed in TEN
buffer (50 mM Tris/HCl pH 8.0, 100 mM NaCl) supplemented with 2.5% Triton X-
100 and protease inhibitor cocktail (PIC; 1 μg/ml apoprotinin, 1 μg/ml leupeptin, 1
μg/ml pepstatin, 5 μg/ml antipain, 157 μg/ml benzamide) through micro-tip soni-
cation. Inclusion bodies were collected by centrifugation (30 min, 2.500 × g, 4 °C),
washed three times in TEN buffer with, and then three times in TEN buffer
without, Triton X-100. Inclusion bodies were diluted 1:10 by dropwise addition
into 25 mM Na+PO4 pH 7.0, 100 mM NaCl, 6 M guanidine hydrochloride, 1 mM
EDTA and 10mM DTT while stirring, and stirred overnight at 4 °C. Next, the
suspension was diluted 1:10 by dropwise addition to 25 mM Na+PO4 pH 7.0, 100
mM NaCl, 1 mM EDTA, and 2.2% lauryldimethylamine oxide (LDAO), and stirred
overnight at 4 °C. Finally, the suspension was diluted 1:10 by dropwise addition to
25 mM Na+PO4 pH 7.0, 10 mM NaCl, 1 mM EDTA, 0.1 % LDAO, and 1 mM
DTT, stirred overnight at 4 °C, and loaded on a Fractogel EMD-SE Hicap cation-
exchange column (Merck Millipore). VDAC proteins were eluted with a linear
NaCl concentration gradient in 25 mM Na+PO4 pH 7.0, 10 mM NaCl, 1 mM
EDTA, 1 mM DTT, and 0.1% LDAO on a ÄKTAprime plus protein puriﬁcation
system (GE Healthcare Life Sciences). Peak fractions were pooled, concentrated on
an Amicon Ultra-4 unit (MWCO 10 kDa; Merck Millipore), and loaded on a
Superose 12 10/300 GL size exclusion column (GE Healthcare Life Sciences).
Elution was in 10 mM Tris/HCl, pH 7.0, 100 mM NaCl, and 0.05% LDAO. Puriﬁed
VDAC proteins in peak fractions were pooled, quantiﬁed using Amido Black58,
and then reconstituted at a concentration of 1 mg/ml in egg PC vesicles supple-
mented with 1 mol% NBD-PC at a protein to lipid ratio of 1:300 (mol/mol). To this
end, egg PC and NBD-PC dissolved in CH3Cl were dried and dissolved in buffer R
(100 mM KCl, 10 mM MOPS/Tris pH 7.0) by vortexing and sonication. LDAO was
added in 10-fold molar excess over lipids. The concentration of LDAO in the
protein sample was adjusted to that in the lipid sample. Both samples were incu-
bated separately at RT for 20 min, mixed at a 1:1 (v/v) ratio, and incubated again
for 30 min. SM2 Biobeads (Bio-Rad Laboratories) pretreated according to the
manufacturer’s instructions were added to the lipid–protein mixture in 30-fold
excess over detergent (w/w). After incubation overnight at 4 °C on a rotating wheel,
the beads were removed by centrifugation and the proteoliposome-containing
supernatant was aliquoted, snap-frozen in liquid N2, and stored at −80 °C. To
check reconstitution efﬁciency, an aliquot of the proteoliposomes was subjected to
density ﬂotation analysis. To this end, proteoliposomes were mixed 1:1 (v/v) with
80% Accudenz (Accurate Chemical & Scientiﬁc Corporation, USA) in buffer R,
transferred to the bottom of a 5 ml ultracentrifuge tube, and overlayed with 30%,
20%, 10%, and 0% Accudenz prepared in reconstitution buffer. After centrifugation
for 1 h at 100,000 × g at 4 °C, 10 × 0.5 ml fractions were collected from top to
bottom. Fractionation proﬁles of NBD-PC and VDACs were determined by TLC
analysis and SDS-PAGE followed by Coomassie blue staining, respectively.
Photoafﬁnity labeling of recombinant VDACs. Liposomes used for photoafﬁnity
labeling of reconstituted VDACs were prepared from a deﬁned lipid mixture
(DOPC/DOPE/pacLipid, 80/20/1 mol%) in CHCl3/methanol (9/1, v/v). In brief, 10
μmol of total lipid was dried in a Rotavap and the resulting lipid ﬁlm was resus-
pended in 1 ml buffer L (50 mM Tris-HCl, pH 7.4, 50 mM NaCl) by vigorous
vortexing and sonication, yielding a 10 mM lipid suspension. Liposomes with an
average diameter of ~100 nm were obtained by sequential extrusion of the lipid
suspension through 0.4, 0.2, and 0.1 μm track-etched polycarbonate membranes
(Whatman-Nucleopore) using a mini-extruder (Avanti Polar Lipids). VDAC
proteoliposomes were diluted in buffer R to a ﬁnal protein concentration of 0.1 mg/
ml, mixed with an equal volume of 10 mM liposomes containing 1 mol% pacLipid,
and incubated for 30 min at 37 °C with gentle shaking. For the experiments shown
in Figs. 3 and 4, VDAC proteoliposomes were incubated with pacLipids added
from ethanolic stocks (0.2 nmol in 100 μl reaction volume, unless indicated
otherwise). To determine the impact of pH on pacCer labeling of VDAC1, VDAC1
proteoliposomes were collected by high-speed centrifugation and then resuspended
in the following buffers prior to photolabeling: (a) 100 mKCl, 50 mM MES-NaOH
pH 5.0; (b) 100 mKCl, 50 mM MES-NaOH pH 6.0; (c) 100 mKCl, 10 mM MOPS/
Tris pH 7.0; (d) 100 mKCl, 50 mM HEPES pH 8.0. The mixtures were placed on ice
and irradiated for 90 s using a 1000W mercury lamp equipped with a dichroic
mirror and a 345 nm bandpass ﬁlter (Newport) at 30 cm distance. Proteins were
recovered by chloroform–methanol precipitation after external addition of BSA as
a carrier and the air-dried protein pellet was dissolved in 1% SDS in PBS with
vigorous shaking for 10 min at 70 °C. Samples were click-reacted with 80 µM
AF647-N3 in 1 mM TCEP (Tris(2-carboxyethyl)phosphine hydrochloride), 0.1 mM
TBTA (Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl] amine), and 1 mM CuSO4 for
1 h at 37 °C. After addition of 0.25 vol of 5× Sample buffer (0.3 M Tris/HCl, pH 6.8,
10% SDS, 50% glycerol, 0.025% bromphenol blue, and 10% β-mercaptoethanol),
samples were boiled for 5 min at 95 °C, subjected to SDS-PAGE and analyzed by
IGF using a Typhoon FLA 9500 (GE Healthcare) with a 635 nm laser and LPR
ﬁlter. Fluorescence intensities were quantiﬁed using ImageQuant TL software.
Next, gels were stained with Coomassie blue and the amount of recombinant
protein was determined by measuring the staining intensity using Image Lab
5.2 software (Bio-Rad Laboratories). Fluorescence intensities of recombinant pro-
tein were corrected for background ﬂuorescence in the same lane and then divided
by the total amount of protein. The speciﬁc ﬂuorescence intensity of UV-irradiated
protein was determined after subtraction of ﬂuorescence intensity of non-UV-
irradiated protein.
Identiﬁcation of pacCer-photolabeled proteins. Post-nuclear supernatants, cyto-
sol, total membranes, and membrane fractions enriched in mitochondria or ER were
prepared from HeLa cells25. Subcellular fractions were diluted in buffer R (10mM
Tris, pH 7.4, 0.25M sucrose) supplemented with 0.1mM PMSF and PIC to 0.45–0.70
mg/ml total protein and then mixed with an equal volume of 10mM liposomes
containing 1mol% pacCer prepared in buffer R as above. Samples were incubated for
60min at 37 °C with gentle shaking, placed on ice, and then UV irradiated for 90 s.
Proteins were recovered by chloroform–methanol precipitation, click reacted with
AF647-N3 and then subjected to IGF as above. For identiﬁcation of the mitochondria-
associated 33kDa-protein band, an HeLa cell-derived membrane fraction enriched in
mitochondria (20 µg total protein) was photolabeled with pacCer as above. Experi-
ments in which pacCer was omitted from the liposomes served as controls. Proteins
were recovered by chloroform–methanol precipitation, dissolved in 50 µl 1% SDS PBS
by vigorous vortexing and sonication in a water bath. After addition of 50 µl PBS, the
sample was click-reacted with 1mM TAMRA-Biotin-N3 as above. Next, two-third of
the sample was mixed with 100 µl slurry of NeutrAvidin™ Agarose Resin (Thermo
Fisher Scientiﬁc, USA) pre-equilibrated in PBS/0.5% SDS and incubated for 2 h at RT
while shaking. The beads were washed ﬁve times in 0.6ml PBS/0.5% SDS and then
incubated in Sample buffer for 5min at 95 °C to elute bound proteins. Proteins in
total input, ﬂow-through, wash, and eluate were recovered by chloroform–methanol
precipitation and processed for IGF analysis as above. The pacCer-labeled 33-kDa-
protein band in the eluate fraction was excised from the gel and digested by trypsin
(Promega, V5111) for 6 h at 37 °C. Protein fragments were collected, concentrated,
and analyzed by LC-MS/MS in an amaZon Spped ETD ion Trap mass spectrometer
(Bruker, USA) connected to an UltiMate 3000 nano LC system (Thermo Fisher
Scientiﬁc). Peptides were separated on a C18 column using a two-buffer system with
water/acetonitrile/formic acid (99/1/0.1, v/v/v) and water/acetonitrile/formic acid (20/
80/0.1, v/v/v). Raw MS data were converted to peak lists using Data Analyzer 4.1
(Bruker, USA) and noise ﬁltered using an in-house developed script. The spectra were
searched with Mascot (precursor mass tolerance 0.8Da; product mass tolerance 0.4
Da; 2 missed cleavages) against all human proteins in the Swissprot (v56.2) database.
Peptide identiﬁcations were accepted with a score greater than 20 and a p-value
smaller than 0.01, and proteins were identiﬁed with at least two unique peptides.
MD simulations. For VDAC MD simulations, a well-resolved structure of mouse
VDAC1 (PDB: 4C69 at 2.8 Å resolution)41 was selected as a main template. This
structure shares a β-barrel backbone RMSD of 1.7 Å with a structure of VDAC2
from zebraﬁsh (PDB: 4BUM)42. Based on the assumption of identical secondary
structures, VDAC1 side chains were mutated to the mouse sequences of VDAC2
(NCBI ID:NP_035825.1) and VDAC3 (NCBI ID:NP_035826.1) to obtain struc-
tures of all three isoforms for comparison using the PyMOL software. The
mutation process was semi-automated and leveraged the used CG representation
(see below), in which side chains are represented by up to four particles and are
therefore simple to replace. The N-terminal α-helix of the VDAC2 was truncated to
match VDAC1 sequence length (with no impact to lipid interactions because the
helix sits inside the channel’s β-barrel). VDACs were embedded in an outer
mitochondrial membrane mimic with about 630 lipids using the insane script59.
Membrane composition was based on Horvath and Daum43, with a mixture of
POPC/POPE/POPI/cholesterol (52/14/19/15, mol%) in the inner leaﬂet and
POPC/POPE/POPI/cholesterol (42.5/32/5/15.5, mol%) supplemented with 5 mol%
C16-ceramide in the outer leaﬂet. About 150 mM NaCl was added to the system,
plus an excess of Na+ ions to reach charge neutrality. The Martini coarse-grain
(CG) force ﬁeld60 was used to model the simulated systems, together with the
ElNeDyn elastic-network approach to restrain the protein secondary structure61.
Simulations were run with GROMACS version 5.062 in the isothermal–isobaric
(NpT) ensemble, at 300 K and 1 bar. Temperature was controlled using the v-
rescale thermostat with a coupling constant of 1.0 ps. Pressure was coupled semi-
isotropically, independently in xy and z, using the Parrinello–Rahman barostat
with a coupling constant of 12.0 ps and a compressibility of 4.5 × 10−5 bar−1.
Standard Martini parameters were used to represent interparticle interactions60,63:
electrostatic interactions were modeled with a Coulombic potential cutoff at 1.2
nm, shifted to zero along the entire range, in conjunction with an implicit
screening constant of 15. The Van der Waals interactions were calculated using a
shifted Lennard–Jones potential, with a cutoff of 1.2 nm and a shift to zero from
0.9 nm. A simulation integration time step of 20 fs was used, and particle neighbor-
searching was performed over a 1.4 nm radius once every 10 simulation steps. As
the apparent pKa of the membrane-facing glutamate E73 in VDAC1 is closely
tuned to the physiological pH of the cytosol (pKa ~7.4)51, main simulations of
VDAC1 and VDAC2 were initially done with deprotonated E73/E84 in six repli-
cates (0.3 ms total) each. Other simulated systems include VDACs with protonated
E73/E84, or with E73Q/E84Q or E73D/E84D mutations. VDAC1 with deproto-
nated E73 was also simulated in 100% DMPC. The total simulation time for all
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systems was 1.23 ms (Supplementary Table 2). Trajectories were saved and ana-
lyzed every 600 ps.
Simulation analysis. Two main types of analysis were performed: contact analysis
and space occupation analysis. Contact analyses were performed either as residue-
discriminated analyses or as residence-time distributions. Residue-discriminated
contacts were calculated by ﬁnding all frames of ceramide (particles AM1 or AM2)
or cholesterol (particle ROH) head groups within 7 Å of any relevant residue
particle. To allow comparison between simulations of different lengths, the number
of in-contact frames was normalized by the total number of frames. Contact
residence-time distributions were plotted by logarithmically histogramming the
duration of all individual continuous binding events of each single ligand to the
VDAC-binding site. To correctly convey the impact of long-term binding events, y-
values indicate the sum of binding durations in that bin. To compare between
simulations of different duration, the y-values were further normalized for the
respective total simulation time. Analysis of continuous contact times is very
sensitive to the use of a sharp cutoff, and long binding events will be under-
estimated if the ligand brieﬂy drifts past the threshold, even if not actually leaving
the binding site. To correct for this, for binding duration analysis a contact was
deﬁned when a head group particle (AM1 or AM2 in ceramide; PO4 or NC3 in
DMPC) came within 8 Å of at least two groups of residues, out of three deﬁned on
the β-strands that compose the binding site (VDAC1 residues 58–60, 73–75, and
81–83). Spuriously brief contacts, or spuriously brief losses of contact, were further
ﬁltered by applying a smoothing window ﬁve-frames wide; if there were contacts
on three or more of those frames the center frame was set to be in-contact,
otherwise it was set to be not-in-contact. Binding events that were still bound at the
end of a simulation run were disregarded. Space occupation analyses were per-
formed by gridding the simulation box at 5 Å spacing and comparing ceramide
versus cholesterol occupancy. The number of occupied frames for each cell was
calculated for the entire simulation time, and then normalized by the total number
of frames, yielding a grid of occupancy values ranging from zero (never present in
that cell) to one (always present). Occupancy volumes were drawn as iso-
occupancy surfaces at given thresholds (10% for ceramide, 20% for cholesterol),
adjusted to compensate for the difference in the number of lipid molecules. To
allow meaningful occupancy surfaces to be drawn relative to the protein, its
position and rotation in the xy plane were aligned beforehand across all analyzed
trajectories.
Algorithms and statistical analysis. Analysis algorithms were programmed in
Python, using MDAnalysis (https://www.mdanalysis.org)64,65 and NumPy66
packages. The MDreader package (https://github.com/mnmelo/MDreader) was
used to allow analysis parallelization, which was essential in tackling the multi-
gigabyte trajectory analysis in a short time. Two types of statistical analyses were
performed on the distribution of contact residence times: data are presented as
time-weighted average values, with 95% conﬁdence intervals estimated by a 10k-
resample bootstrapping of the time-weighted averaging, and the signiﬁcance level
for the difference between binding durations was obtained by a continuity-
corrected one-tailed Mann–Whitney–Wilcoxon U test. The Visual Molecular
Dynamics (VMD) software67 was used to create images and movies.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Data supporting the ﬁndings of this manuscript are available from the corresponding
authors upon reasonable request. A Reporting Summary for this Article is available as
a Supplementary Information ﬁle. Full scans of gels and blots are provided
in Supplementary Information. The source data underlying Figs. 3d, 4b, 5b, 6c, 7b, 7c
and Supplementary Table 1 are provided as a Source Data ﬁle.
Code availability
Trajectory analysis programs, as well as protein structures and models, are available from
the download section of the Melo lab’s website, at http://www.itqb.unl.pt/labs/multiscale-
modeling/.
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